贝伐珠单抗致过敏性休克1例  

A case report of anaphylactic shock induced by bevacizumab

作　　者：刘静静 康艳生 王晓琴 张伟 张鹤凤 王彤 Jing-Jing LIU;Yan-Sheng KANG;Xiao-Qin WANG;Wei ZHANG;He-Feng ZHANG;Tong WANG(Department of Pharmacy,The First Hospital of Yulin(The Second Affiliated Hospital of Yan'an University),Yulin 719000,Shaanxi Province,China)

机构地区：[1]榆林市第一医院(延安大学第二附属医院)药剂科,陕西榆林719000

出　　处：《药物流行病学杂志》2023年第1期103-106,共4页Chinese Journal of Pharmacoepidemiology

基　　金：榆林市科学技术研究与开发项目(【2019】185号-35)。

摘　　要：分析1例贝伐珠单抗致过敏性休克的临床特点和相关因素,为临床安全用药提供参考。1例右肺腺癌患者第10次使用贝伐珠单抗进行单药化疗,出现心慌、气短、口唇发绀、指脉氧饱和度降低、心率加快、血压测不出、短暂全身抽搐和一过性心跳停止,经抢救后患者痊愈,并终止了贝伐珠单抗对原发病的治疗。贝伐珠单抗为低敏性药物,但多疗程治疗的肿瘤患者应警惕严重的/罕见的过敏反应,建议在具备抢救设施的环境中在使用。To analyze the clinical characteristics and related factors of a case report of anaphylactic shock induced by bevacizumab and provide safe references for clinical prescriptions.The patient received single-agent chemotherapy with bevacizumab for the 10th time for right lung adenocarcinoma,which presented with symptoms such as palpitation,shortness of breath,cyanosis of the lips,decreased pulse oxygen saturation,increased heart rate,undetectable blood pressure,transient convulsions and transient cardiac arrest.After rescue,the patient recovered and stoped the treatment of bevacizumab monoclonal antibody.Bevacizumab has a low incidence of anaphylaxis,however the tumor patients with multiple courses of treatment should be alert to severe/rare allergic reactions.Therefore,it is recommended to use it in an environment with rescue facilities.

关 键 词：贝伐珠单抗 过敏性休克 药品不良反应 病例报告 

分 类 号：R969[医药卫生—药理学]